GSTM3 and pachyonychia congenita: Moreover, the increased levels of GSTM3TV2 in PC tissues have been significantly associated with worse prognosis, indicating that GSTM3TV2 may be a novel prognostic marker and therapeutic target in PC (Xiong et al., 2019).